Neuroone Medical Technologies Corp NMTC

$1.10 +0.03 (2.33%)

Valuation

Market cap
10,198,000
Revenue TTM
$12,100,000
Net income TTM
$-3,610,000
PE ratio
0.00
Forward PE
—
Profit margin
-29.83%
Debt to equity
0.00

Trading

Volume
108,327
Avg volume
418,588
Day's range
$1.05 – $1.14
Shares out
9,106,000
Stochastic %K
29%
Beta
0.77
Analysts
Strong Sell
Price target
$7.27

Price

Company profile

NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia,...

Show more

NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.

Industry
Medical Devices
Sector
Healthcare
Phone
952 426 1383
Website
https://nmtc1.com
Address
7599 Anagram Drive, Eden Prairie, United States

Latest news

Stocktwits

leapingalpha Oct 13, 6:47 PM
$NMTC
0 replies
JohnStuartMill Oct 13, 3:54 PM
$NMTC Now if only all these hype press releases can get the price up.
0 replies
NeuroOne_IR Oct 13, 2:23 PM
$NMTC Our Evo electrodes and OneRF brain ablation system will be showcased alongside Zimmer Biomet and Monteris technologies at the 2026 CNS Annual Meeting, October 31–November 4 in Washington, D.C., at Booth #649. Commercialized through our distribution partnership with Zimmer Biomet, these technologies support electrical recording and targeted radiofrequency ablation. OneRF enables diagnostic recording and ablation using the same sEEG electrode, connecting information gathering with treatment. Together with ROSA Brain’s robotic planning and guidance and NeuroBlate’s laser ablation, our products contribute to a portfolio spanning navigation, localization and ablation. CNS provides an opportunity for neurosurgeons to explore these complementary capabilities and see the practical role of NeuroOne’s technology within the broader workflow.
1 replies
IncognitoBull Oct 12, 12:40 PM
$NMTC i can not even imagine watching my 10 yr old child have 50 seizures in 3 days.... our tech needs to reach more people soon.
1 replies
prismmarketview Oct 9, 2:53 PM
$NMTC: R&D subaward with Dartmouth on an NIH BRAIN Initiative project to sense brain chemistry in real time → Goal: add neurotransmitter sensing to NeuroOne’s sEEG electrodes (electrical activity + chemistry) → ~$1M first-year grant goes to the whole team (Dartmouth, VA, Beth Israel Deaconess, NeuroOne) → NeuroOne’s share: ~$200K through April 30, 2027; more expected in the following two years, amounts unspecified Caveats: research initiative only. No completed human testing, product timeline, regulatory pathway, or sales forecast disclosed. $NMTC #MedTech https://prismmarketview.com/neuroone-joins-1-million-nih-funded-project-to-track-brain-chemistry-in-real-time/
0 replies
NeuroOne_IR Oct 9, 12:22 PM
$NMTC Our sEEG electrodes record electrical activity in the brain. The Dartmouth-led research project seeks to add another layer: neurotransmitter signaling. Measuring both simultaneously could help researchers connect electrical activity with changes in brain chemistry, with the goal of developing real-time monitoring tools to support understanding, diagnosis and treatment of neurological and psychiatric disorders. Our role is to explore how our sEEG technology can incorporate neurochemical sensing alongside electrical recording. This capability remains in development toward potential use in humans. Our platform already supports recording, stimulation and ablation. Through NIH-funded research with Dartmouth and participating medical centers, we are investigating an additional sensing capability, demonstrating how our technology can support research at established academic and medical institutions. We look forward to advancing this work with Dartmouth and the broader research team.
0 replies
NeuroOne_IR Oct 8, 8:23 PM
$NMTC Today, we announced an agreement with Dartmouth to support research into neurotransmitter sensing using our sEEG electrodes. Dartmouth received approximately $1 million in NIH funding for the project’s first year. Under our subaward agreement, we will receive approximately $200,000 through April 30, 2027, with additional funds expected during the following two years. The objective is to combine electrical recording with neurochemical sensing, working toward potential use in humans. This agreement places our sEEG technology within a Dartmouth-led, NIH-funded research project alongside the VA Medical Center and Beth Israel Deaconess Medical Center. It adds a new institutional research collaboration to the commercial progress reflected in our preliminary FY2026 results and open purchase orders entering FY2027. We’ll continue sharing updates as this research progresses.
2 replies
50shadesoftrades Oct 8, 8:01 PM
$NMTC $NMTC NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology https://www.stocktitan.net/news/NMTC/neuro-one-joins-dartmouth-led-research-team-on-1-million-nih-grant-skto6xieibms.html
0 replies